Ziccum runs Feasibility and Application studies as part of formal collaboration agreements with big pharma development teams, biotech startups and university research departments. These projects are a crucial part of the company’s business model, ultimately aiming to develop and license novel thermostable formulations of next-generation vaccines and biomolecules.
The Ziccum pipeline of external projects is depicted in a portfolio overview. This gives a general representation of the key steps towards the desired commercialization by entering into license agreements, licensing the LaminarPace technology for specific applications, and the current status of each project. The actual progress in a specific project may proceed via alternative or additional steps, and the timeline varies greatly depending on the resulting read-outs and the counterpart preferences.
Pharmaceutical development in general is subject to very strict confidentiality, and certain collaborations are given without partner name publication, until name disclosure is possible.
The company also pursues earlier dialogues with other counterparts in on-going business development efforts.
Project portfolio overview as of March 31, 2023
